Aduro Biotech Announces the Departure of Natalie R. Sacks, M.D.
19 September 2018 - 11:00PM
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Natalie R.
Sacks, M.D. has resigned from her position as the company’s chief
medical officer effective October 1, 2018. Dr. Sacks will continue
to provide counsel to the company and facilitate her transition
through a consulting agreement.
“On behalf of the management team and Board of Directors, I’m
grateful for the significant contributions Natalie made over the
past three years and we wish her the best in her next endeavor,”
commented Stephen T. Isaacs, chairman, president and chief
executive officer of Aduro. “During her tenure, Natalie has played
an integral role in defining the development strategy for our lead
STING agonist ADU-S100 and for our anti-APRIL antibody BION-1301,
two first-in-class assets that have potential to impact the
treatment landscape for patients with a myriad of serious diseases.
The company remains well-positioned and on track to advance
ADU-S100 and BION-1301 toward achieving important clinical
milestones in 2018 and over the next 12 months.”
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that are intended to transform the
treatment of challenging diseases. Aduro's technology platforms,
which are designed to harness the body's natural immune system, are
being investigated in cancer indications and have the potential to
expand into autoimmune and infectious diseases. Aduro's STING
pathway activator platform is designed to activate the STING
receptor in immune cells, which may result in a potent
tumor-specific immune response. ADU-S100 (MIW815) is the first
STING pathway activator compound to enter the clinic and is
currently being evaluated in a Phase 1 clinical trial as a single
agent and in combination with ipilimumab and in a Phase 1b
combination trial with spartalizumab (PDR001), an investigational
anti-PD1 immune checkpoint inhibitor. Aduro’s B-select monoclonal
antibody platform, including BION-1301, an anti-APRIL antibody, is
comprised of a number of immune modulating assets in research and
development. Aduro's pLADD program is based on proprietary
attenuated strains of Listeria that have been engineered
to express tumor neoantigens that are specific to an individual
patient’s tumor. Other Listeria strains for lung and
prostate cancers are being advanced by a partner. Aduro is
collaborating with leading global pharmaceutical companies to
expand its products and technology platforms. For more information,
please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include statements
regarding our intentions or current expectations concerning, among
other things, the potential for ADU-S100 and BION-1301 to impact
the treatment landscape for patients with a myriad of serious
diseases, the advancement of ADU-S100 and BION-1301 toward
achieving clinical milestones in 2018 and over the next 12 months,
the timing of clinical data, and our ability to advance our drug
development programs on our own or with our collaborators. In some
cases you can identify these statements by forward-looking words
such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,”
“project,” “expect” or the negative or plural of these words or
similar expressions. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause actual results and events to differ
materially from those anticipated, including, but not limited to,
our history of net operating losses and uncertainty regarding our
ability to achieve profitability, our ability to develop and
commercialize our product candidates, our ability to use and expand
our technology platforms to build a pipeline of product candidates,
our ability to obtain and maintain regulatory approval of our
product candidates, our ability to operate in a competitive
industry and compete successfully against competitors that have
greater resources than we do, our reliance on third parties, and
our ability to obtain and adequately protect intellectual property
rights for our product candidates. We discuss many of
these risks in greater detail under the heading “Risk Factors”
contained in our quarterly report on Form 10-Q for the quarter
ended June 30, 2018, which is on file with the Securities and
Exchange Commission. Forward-looking statements are not guarantees
of future performance, and our actual results of operations,
financial condition and liquidity, and the development of the
industry in which we operate, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. We assume no obligation
to update our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Contact: |
|
Media
Contact: |
Jennifer
Lew |
|
Aljanae
Reynolds |
Chief Financial
Officer |
|
510-809-2452 |
510-809-4816 |
|
press@aduro.com |
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Apr 2024 to May 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From May 2023 to May 2024